Pet Meds Adapted from Human Therapies

Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

© ISTOCK.COM/3BUGSMOM

Around Christmas 2010, University of Minnesota researcher Mark Suckow received terrible news: his family’s twelve-and-a-half-year-old Labrador retriever, Sadie, had squamous cell carcinoma that the vet deemed fatal. But Suckow’s children refused to accept that outcome—their father, after all, was both a trained veterinarian and an expert on tissue-based cancer vaccines. Couldn’t he make one for Sadie? Although his research was in rodent models, he agreed to give it a try. Using a harvested bit of Sadie’s tumor, he created a vaccine by breaking the tumor down into individual cells, inactivating them with a fixative, and mixing them with a bulking agent. Within a couple of weeks—soon after Sadie was injected with the second dose—the tumor stopped spreading and began to shrink. Sadie survived nearly three ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jenny Rood

    This person does not yet have a bio.

Published In

October 2016

30th Anniversary Issue

How life science research has changed since 1986

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours